Lyra Therapeutics, a Phase 2 biotech developing an implantable drug-device for chronic rhinosinusitis, raised $56 million by offering 3.5 million shares at $16, the high end of the range of $14 to $16. Lyra Therapeutics plans to list on the Nasdaq under the symbol LYRA. BofA Securities, Jefferies and William Blair acted as lead managers on the deal.
The article ENT biotech Lyra Therapeutics prices IPO at $16 high end originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
